Method of preventive poliomyelitis vaccination in far north

FIELD: medicine; pediatrics.

SUBSTANCE: by the first vaccination of 3-18 months old children vaccination is performed at least over 60 days after their arrival to Far North regions from other climatic zones.

EFFECT: high vaccination efficiency due to taking in consideration processes of child organism adaptation to a change of climatic zones.

7 ex

 

The invention relates to medicine, namely to Pediatrics, and can be used to vaccinate children against polio in the Far North.

The known method the primary mass vaccination of children against polio by introducing a live vaccine of Sabina (JWS) [1]. Vaccination by a known method is performed in three stages: the first vaccination for the child reaches the age of 3 months; the second vaccination at 4.5 months and the third vaccination in 6 months.

However, in the known method of vaccination there is no regional approach in its implementation, which reduces the effectiveness of the vaccine against polio and the need for repeated vaccination complex. Immunisation under the national vaccination calendar polio does not take into account the processes of adaptation of children to the Far North. Instill in all children aged from 3 to 18 months, as residing in the Far North, and those who come in this period from other regions. It is known that the change of region of residence, even temporarily, leads to disruption of the processes of adaptation of the child to the conditions of the Far North, and the formation of immunity in vaccinated in the Far North is more a long time than in the middle latitudes. This is especially important for children p is Islah inhabitants of the Far North, coming from other climatic zones of the country.

The objective of the invention is to increase the efficiency of the method of vaccination against polio.

The invention consists in the fact that children aged from 3 to 18 months of arriving in the Extreme North and be the primary polio vaccine according to the vaccination Calendar, vaccinated with live vaccine of Sabina not earlier than 60 days after arrival in the Far North of the other climate zones.

A similar approach to the prevention of polio allows to take into account adaptation processes occurring in the body of the child when changing latitudinal zones.

The method is as follows.

When the initial polio vaccination of children aged from 3 to 18 months of arriving in the Extreme North of the other regions, instill IS not earlier than 60 days after arrival.

Example 1. Sadyrin N. Vaccinated IS 25 days after arrival in the Extreme North at the age of 5 months. Subsequent vaccination performed at the age of 6,5 and 8 months. 12 months after the last immunization antibodies to viruses polio I, II and III serotypes were determined respectively in titles <1:4, 1:4 and <1:4 - seronegative. The child is susceptible to the virus of poliomyelitis.

Example 2. Black And. Vaccinated IS through 30 d is after her arrival in the Extreme North at the age of 5 months. Subsequent vaccination performed at the age of 6,5 and 8 months. 12 months after the last immunization antibodies to viruses polio I, II and III serotypes, respectively, were determined in titers of 1:4, <1:4 and 1:4 - seronegative. The child is susceptible to the virus of poliomyelitis.

Example 3. Borisevich, S. Vaccinated IS 35 days after arrival in the Extreme North at the age of 5 months. Subsequent vaccination carried out at the age of 6,5 and 8 months. 12 months after the last immunization antibodies to viruses polio I, II and III serotypes were determined respectively in titles <1:4, <1:4 <1:4 - seronegative. The child is susceptible to the virus of poliomyelitis.

Example 4. Drozdova S. Vaccinated IS 40 days after his arrival in the Far North at the age of 4.5 months. Subsequent vaccination carried out at the age of 6 and 7.5 months. 12 months after the last immunization antibodies to viruses polio I, II and III serotypes were determined respectively in titers of 1:4, <1:4 and 1:4 - seronegative. The child is susceptible to the virus of poliomyelitis.

Example 5. Evtukhov J. Vaccinated IS 50 days after arrival in the Extreme North at the age of 6 months. Subsequent vaccination carried out in the age of 7.5 and 9 months. 12 months after the last immunization antibodies to viruses polio I, II and III serotypes were determined respectively in tirah:4, 1:4 <1:4 - seronegative. The child is susceptible to the virus of poliomyelitis.

Example 6. Chertkova Y. Vaccinated IS 55 days after arrival in the Extreme North at the age of 5.5 months. Subsequent vaccination carried out at the age of 7 and 8.5 months. 12 months after the last immunization antibodies to viruses polio I, II and III serotypes were determined respectively in titles <1:4, <1:4 and 1:4 - seronegative. The child is susceptible to the virus of poliomyelitis.

Example 7. Nolacon I. Vaccinated IS 60 days after arrival in the Extreme North at the age of 5 months. Subsequent vaccination performed at the age of 6,5 and 8 months. 12 months after the last immunization antibodies to viruses polio I, II and III serotypes, respectively, were determined in protective titers of 1:64, 1:64 and 1:32 - seropositive. The child is not susceptible to poliovirus.

Only in the Extreme North of the proposed method grafted 453 child. The result of vaccination was determined through the year by immunological examination of children with a different period of time between their arrival in the Extreme North and vaccination. Antibody titers were evaluated in the reaction of the color samples on the level of cultivation. The dilution of serum titer ≤1:4 for the polio virus I, II and III serotypes were considered seronegative children susceptible to poliovirus. Then the AK breeding ≥ 1:8 were evaluated as seropositive children are not susceptible to poliovirus. Studies have shown that the most efficient primary vaccination against polio was achieved by holding it at a time not earlier than 60 days after the arrival of children in the Far North. After vaccination in other terms were recorded significantly more number of children (%) susceptible to poliovirus.

The method creates favorable conditions for adaptation of children when changing latitudinal belts, which improves the efficacy of vaccination of them in the Far North, to avoid further immunological studies and re-vaccination.

Sources of information

1. The national vaccination calendar. The Ministry of health No. 229 dated 20.06.2001.

2. The way revaccination with live vaccine of Sabina in the Far North. EN 2185853 C2, 27.07.2002.

The way of polio vaccination by introducing a live vaccine of Sabina children aged from 3 to 18 months, characterized in that for primary vaccination of children in the Far North vaccine administered no earlier than 60 days after their arrival in the Far North of the other climate zones.



 

Same patents:

FIELD: medicine; pharmacology.

SUBSTANCE: invention claims application of starches substituted by quarterly ammonium groups with substitution degree of 0.4 to 3.0 with the help of a linker, in infection diseases treatment. Suppression of 1 type herpes virus replication by the claimed starches is demonstrated, in comparison to zero antivirus effect of non-modified starches. Minimal inhibiting concentration for staphylococci and mycobacteria is 5-60 g/l.

EFFECT: efficient infection disease treatment by the claimed starches.

5 cl, 7 tbl

FIELD: chemistry, pharmaceuticals.

SUBSTANCE: invention pertains to compounds with formula (I), their pharmaceutical salts or N-oxide used as an inhibitor to replication and/or proliferation of HCV, to the method of inhibiting replication or proliferation of hepatitis C virion using formula (I) compounds, as well as to pharmaceutical compositions based on them. The compounds can be used for treating or preventing infections, caused by hepatitis C virus. In general formula (I) cycle B is an aromatic or non-aromatic ring, which contains two heteroatoms, where X and Y, each is independently chosen from C, CH, N or O, under the condition that, both X and Y are not O and that, both X and Y are not N; U and T represent C; Z represents -CH-; A represents N or -CR2-; B represents -CR3-; D represents N or -CR4-; E represents N or -CR5-; G represents N or -CR6-; J represents N or -CR14-; K represents -CR8-; L represents N or -CR9-; M represents N or -CR10-; R2 and R6, each is independently chosen from a group, consisting of hydrogen, halogen, C1-C6alkyl, substituted C1-C6alkyl, C1-C6alkoxy, C1-C6substituted alkoxy, C1-C6alkoxycarbonyl, cycloheteroalkyl, substituted cycloheteroalkyl, -O-carbamoil, substituted -O-carbamoil, halogen C1-C6alkyl, diC1-C6alkylamino, substituted diC1-C6alkylamino and sylye ethers, where cycloheteroalkyl is a 3-7-member ring, containing 1-2 heteroatoms, chosen from N and O, under the condition that, one of R2 and R6 is not hydrogen; R3 and R5, each is independently chosen from a group, consisting of hydrogen, halogen; R4 represents hydrogen; R7 represents - NR11C(O)R12; R8, R9, R10 and R14, each is independently represents hydrogen; R11 represents hydrogen, C1-C6alkyl; and R12 is chosen from a group, consisting of halogen C1-C6alkyl; where each substituted group is substituted with one or more groups, chosen from -Q, -R40, -OR40, -C(O)R40, -C(O)OR40, where each Q independently represents halogen, R40 and R41 are independently chosen from a group consisting of hydrogen, C1-C6alkyl, C1-C6alkoxy, under the condition that: (i) at least one of A, D, E, G, J, L or M represents N; (ii) not more than one of A, D, E or G represents N; and (iii) not more than one of J, L or M represents N.

EFFECT: obtaining pyridyl-substituted heterocycles for treating and preventing infections, caused by hepatitis C virus.

33 cl, 85 dwg, 101 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science. Medicinal agent applied for prevention and treatment of bird viral influenza is represented with polystibuim. Polystibium inhibits infectious activity of influenza virus.

EFFECT: development of effective method applied for treatment and prevention of bird influenza.

6 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical products and concerns combination for HIV-infection treatment, containing (a) therapeutically effective amount of HIV-protease inhibitor by formula or its pharmaceutically accepted salt or ester and (b) effective amount of rhytonavir or its pharmaceutically accepted salt or ester. Besides, method of improved pharmacokinetics of HIV-protease inhibitor by formula (4) or its pharmaceutically accepted salt or ester, including introduction to an individual requiring such treatment, therapeutically effective amount of rhytonavir or its pharmaceutically accepted salt or ester with therapeutically effective amount of specified HIV-protease inhibitor by formula (4) is described.

EFFECT: offered combination has synergetic action if taken in any molar ratios.

33 cl, 6 dwg, 9 tbl, 4 ex

FIELD: bioengineering.

SUBSTANCE: novel polynucleotide is invented which is produced from the nucleotide sequence of the IFNα-17 gene, containing the single nucleotide polymorphism SNP g771c. Also, the novel polynucleotide is invented which is derived from the natural protein IFNα-17 of the wild type containing SNP G45R.

EFFECT: can be used for producing effective therapeutic agent with antiviral, antiproliferative and/or immunomodulating activity.

13 cl, 5 dwg, 6 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention refers to creation and application of aerosol spray compositions for treatment of diseases or disorders requiring lowering of cell proliferation and/or induction of cell apoptosis, such as neoplastic, autoimmune, viral diseases. Agent contains as active substance vitamin E based composition of structural formula , where R1 is carboxylic acid; R2 and R3 are hydrogen or R4; R4 is methyl, and R5 is alkyl; or where R1 is hydrogen or carboxylic acid; R2 and R3 are hydrogen or R4; R4 is methyl, and R5 is alkenyl.

EFFECT: improved delivery of specified composition by inhalation with intensified antiproliferation activity.

59 cl, 17 dwg, 6 tbl, 35 ex

FIELD: medicine.

SUBSTANCE: method of production of dry polyvalent virus-vaccine includes separate infection of cell culture with strain PC-126 of turkey herpesvirus (virus of Marek's disease 3rd serotype) and one-day chicken infected with chicken herpesvirus (virus of Marek's disease 2nd serotype), incubation, turkey herpesvirus harvest, and sampling of double flag follicles of chicken herpesvirus infected chicken, protective medium addition, separate ultrasonic processing of virus cell mass and flag follicle mass, freezing and drying of end product followed with their mixing. At that chicken herpesvirus strain are sampled for (VMD 2nd serotype) strains "42", "50", "SB-1", inoculated in dosage 10000-50000 functional residual capacity (FRC) for chicken and grown in body within 12-25 days. Follicles processed with ultrasonic is removes, and protective medium processed with ultrasonic and containing released chicken herpesvirus is added equal proportion of processed with ultrasonic clean cell cultures of bird embryos grown within 24-72 hours. Dry polyvalent virus-vaccine contains cell-free lyophilized strain FC-126 of turkey herpesvirus - 3rd serotype of Marek's disease virus in protective medium. In addition virus-vaccine includes cell-free lyophilised strains of chicken herpesvirus - 2nd serotype of Marek's disease virus, produced by any cl.1-5, in protective medium at ratio 2000 FRC /units: 100-5 00 FRC /units, respectively.

EFFECT: vaccine has high immunogenic activity and storage stability.

10 cl, 3 tbl, 4 ex

Poplar-aspen oil // 2326685

FIELD: medicine; pharmacology.

SUBSTANCE: agent contains oil extract of poplar buds and sprouts and oil extract of aspen buds and sprouts with component ratio as follows, mass.%: oil extract of poplar buds and sprouts 20-90, oil extract of aspen buds and sprouts 10-80, mixed oil extract of poplar buds and sprouts and oil extract of aspen buds and sprouts, with component ratio as follows, mass.%: oil extract of poplar buds and sprouts 20-90, oil extract of aspen buds and sprouts 10-80, as well as fat extract of plant raw with plant component ratio as follows, mass.: marsh tea 3, comfrey 3, blueash 2, silver fir 1, common burdock (root) 2, horseheal (root) 1, deer's-tongue 1, horseradish 1, musquash-poison 2, hog bean (herb) 2, hop (cones) 2, cowberry (root) 2, mountain arnica (blossom) 2, ratio of oil extracts and fat extract of plant raw is 1:3 respectively.

EFFECT: agent allows widening range of preventive and therapeutic herbal medicinal agents of antiviral and anti-inflammatory action.

2 cl, 9 ex

FIELD: veterinary; veterinarian virology.

SUBSTANCE: production of dry cultural rinderpest virus-vaccine for minor ruminants includes growing of virus containing raw materials from "45G37/35-K" rinderpest virus strain in cell culture, introduction of protective medium and production of the end product. Passaged cell culture of saiga kidney is used as a cell culture. Infected culture is incubated under roller conditions during 5-7 days with the change of supporting medium each 2-3 days. Virus containing culture is mixed before freeze drying in proportion 1:1, and then freeze dried until moisture mass fraction is no more than 4%. Finally, it is packed into ampoules. The end product contains virus raw materials, peptone, sucrose, gelatine and demineralised water.

EFFECT: high-performance production of standard and innocuous rinderpest virus-vaccine for minor ruminants stable for storage conditions.

2 cl, 3 ex

FIELD: medicine, pharmacology.

SUBSTANCE: mixture of chitosonium glutamate obtained from high molecular chitosan with molecular mass 100-500 kD, and restrictedly depolymerised low polymeric chitosan with molecular mass 0.5-20 kD, is added to the inactivated flue vaccine as an adjuvant; the molecules of chitosan and chitosonium glutamate have free aldehydic groups at one of their free end, and have the deacetylation degree within 60-90%; the concentration of high molecular chitosan is brought to 0.5%, and low polymeric chitosan - to 0.05%, and the parenteral vaccination is performed.

EFFECT: method increases the immunogenicity of inactivated flue accine.

4 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to delivery system for antigen as T-cell, containing, at least, one antigen and loading antigen-presenting cells with specified antigen. Application of T-cell containing at least one antigen is offered in medical product for antigen delivery to lymph node. Application of antigen associated with T-cell containing at least one other antigen causing immune response is offered in medical product for immune response monitoring against at least one other antigen. Application of T-cell containing at least one antigen is offered in medical product for antigen-presenting cells (APC) loading with antigen.

EFFECT: offered method of T-cell production for application under any item mentioned above, including T-cell isolation, T-cell activation, T-cell cultivation and antigen introduction to T-cell, where T-cell is transduced with antigen.

24 cl, 8 ex, 1 tbl, 7 dwg

FIELD: medicine; pharmacology.

SUBSTANCE: invention relates to the composition containing the virus-like particle AP205 (VLP) and antigen. The invention also relates to the method of production of the antigen or antigen determinant, bound to VLP AP205. Antigen- bound VLP AP205 are used for production of compositions for immune response induction. The compositions are used in prevention or treatment of diseases, abnormalities or conditions, including infectious diseases, allergy, cancer, drug abuse, intoxications.

EFFECT: invention is used for efficient induction of auto-specific immune responses.

43 cl, 15 dwg, 1 tbl, 13 ex1

FIELD: medicine, virology, immunology, molecular biology.

SUBSTANCE: invention proposes a composition containing virus-like particle and at least one protein or peptide IL-5, IL-13 or human eotaxine bound with its. Also, invention discloses method for preparing this composition and using, pharmaceutical composition and vaccine composition containing such composition. Proposed compositions can be used in treatment of allergic diseases with an eosinophilic component. Except for, proposed compositions are used especially for effective induction of responses specific for autoantigens.

EFFECT: valuable medicinal properties of composition.

40 cl, 1 tbl, 14 dwg, 11 ex

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with vaccinating female rabbits and their kindles with dry live-culture vaccine out of "B-82" strain followed by weaning the offspring. Moreover, female rabbits should be vaccinated 30 d before kindling, not later. The offspring should be weaned at the age of 28 d due to removing from maternal cells, and vaccination of kindles should be carried out 5-7 d after weaning. The innovation enables to prevent the cases of clinical disease after vaccination of the weaned offspring and suckling kindles.

EFFECT: higher efficiency.

2 ex, 2 tbl

FIELD: veterinary virology, biotechnology.

SUBSTANCE: the suggested vaccine contains an active substance and a target additive. As the active substance it contains the suspension of avirulent and purified antigenic material out of "KPR-96" strain of the virus of swine's reproductive-respiratory syndrome (SRRS), Arteriviridae type, Arterivirus genus, FGU collection "VGNKI" "KPR-96"-DEP in efficient quantity. The vaccine in question induces high level of antibodies against SRRS, provides reliable passive maternal immunity in youngsters up to the age of 25-30 d that enables to protect the youngsters against field virulent SRRS virus in earlier period of life.

EFFECT: higher efficiency.

7 cl, 3 dwg, 7 ex, 16 tbl

FIELD: veterinary.

SUBSTANCE: claimed method includes application of chimera flavivirus, including capsid and non-structural proteins of yellow fever virus, prM protein, and envelope protein of West Nile encephalitis virus as drug for prophylaxis of infection caused by West Nile virus in horses.

EFFECT: prophylaxis of infection caused by West Nile virus in horses.

2 tbl

Antigenic peptides // 2312941

FIELD: peptides, medicine, immunology.

SUBSTANCE: invention relates to novel methods for producing family of antigenic peptides possessing antiviral effect, and to peptide libraries obtained by using indicated methods, and to compositions based on thereof. Method for producing antigenic peptides involves detection of a great number of variable positions in protein site of pathogenic organism; selection of peptide sequence in protein of pathogenic organism comprising a great number of variable positions; selection of one or more substituting amino acid residues for one of variable positions or sequences possessing antigenic affinity with amino acid residues in variable position of this protein in natural conditions by using a matrix of antigenic similarity of amino acids showing possibility for substitution of one amino acid residue with another residue and with retaining interaction of antibody with antigen and corrected in correspondence with amino acids frequencies in hypervariable sites; incorporation of selected substituting amino acid residues into peptide sequence; synthesis of family of antigenic peptides. Also, invention relates to a method for calling the immune response and to a method for diagnosis of HIV-infection by using family of peptides prepared according to methods of the invention.

EFFECT: valuable biological and medicinal properties of peptides, improved preparing method.

233 cl, 43 tbl, 1 dwg, 5 ex

FIELD: virology, immunology, medicine.

SUBSTANCE: invention relates to genomic RNA of JEV Korea isolate with nucleotide sequence of SEQ ID NO:15, as well as to infective cDNA obtained from genomic RNA useful in therapy, vaccination, and diagnosis. Also described are recombinant vector containing infective cDNA, method for production thereof, method for production of JEV infective RNA-transcript, synthetic JEV and vaccine against JEV.

EFFECT: new methods for medicine applications.

26 cl, 40 dwg, 5 tbl, 10 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to using of lipopherol-liposomal preparation of antioxidant action for intravenous administration as protective medium. Said lipopherol contains soy psospholipids, DL-alpha-tocopherol, sorbitol-phosphate buffer. Protective medium of present invention prevents infection of bovine spongiform encephalopathy.

EFFECT: bioactive vaccines of high quality and immunity.

2 ex, 1 tbl

FIELD: virology.

SUBSTANCE: porcine vaccine includes plasmid including gene of PRRS virus. PRRS gene is selected from group of E, ORF3, and M genes. Vaccine excites immune response against PRRS virus and is useful in pig breeding.

EFFECT: new vaccine against porcine respiratory and reproductive pathologies.

10 cl, 25 dwg, 26 ex

FIELD: biotechnology, veterinary science.

SUBSTANCE: invention relates to therapeutic vector used in therapy of infectious diseases in cats that comprises at least one foreign nucleic acid each of that (a) encodes protein taken among the group consisting of feline protein CD28 represented in SEQ ID NO:8 or its immunogenic moiety; feline protein CD80 represented in SEQ ID NO:2 or 3, or its immunogenic moiety; feline protein CD86 represented in SEQ ID NO:6 or its immunogenic moiety, or feline protein CTLA-4 represented in SEQ ID NO:10 or its immunogenic moiety; and (b) nucleic acid that is able to be expressed in insertion of vector in the corresponding host. Indicated therapeutic vector is used in effective dose as component of vaccine against infectious diseases in cats for their immunization and in methods for enhancement or inhibition of immune response in cats and reducing or eradication of tumor in cats. Invention provides stimulating the activation and proliferation of T cells and to enhance effectiveness of control of infectious diseases in cats.

EFFECT: valuable biological properties of recombinant virus.

41 cl, 13 dwg

Up!